Dong HQ, Fu XF, Wang MY, Zhu J. Research progress on reactive oxygen species production mechanisms in tumor sonodynamic therapy. World J Clin Cases 2023; 11(22): 5193-5203 [PMID: 37621595 DOI: 10.12998/wjcc.v11.i22.5193]
Corresponding Author of This Article
Jiang Zhu, MD, PhD, Doctor, Professor, Department of Ultrasound, Women's Hospital, Zhejiang University School of Medicine, No. 1 Xueshi Road, Hangzhou 310000, Zhejiang Province, China. zhujiang1046@zju.edu.cn
Research Domain of This Article
Radiology, Nuclear Medicine & Medical Imaging
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
He-Qin Dong, School of Medicine, Shaoxing University, Shaoxin 312000, Zhejiang Province, China
Xiao-Feng Fu, Min-Yan Wang, Jiang Zhu, Department of Ultrasound, Women's Hospital, Zhejiang University School of Medicine, Hangzhou 310000, Zhejiang Province, China
Author contributions: Dong HQ wrote the manuscript; Wang MY and Fu XF contributed equally to this work; Wang MY and Fu XF were mainly responsible for data collection and figure scheduling; Jiang Zhu were responsible for manuscript modification; all authors have read and approve the final manuscript.
Supported bythe National Natural Science Foundation of China, No. 82272004 and No. 81974470, and by the Nature Science Foundation of Zhejiang Province, No. LZ22H180001.
Conflict-of-interest statement: All the authors have no conflict-of-interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jiang Zhu, MD, PhD, Doctor, Professor, Department of Ultrasound, Women's Hospital, Zhejiang University School of Medicine, No. 1 Xueshi Road, Hangzhou 310000, Zhejiang Province, China. zhujiang1046@zju.edu.cn
Received: March 23, 2023 Peer-review started: March 23, 2023 First decision: April 19, 2023 Revised: April 27, 2023 Accepted: May 22, 2023 Article in press: May 22, 2023 Published online: August 6, 2023 Processing time: 133 Days and 3.7 Hours
Abstract
In recent years, because of the growing desire to improve the noninvasiveness and safety of tumor treatments, sonodynamic therapy has gradually become a popular research topic. However, due to the complexity of the therapeutic process, the relevant mechanisms have not yet been fully elucidated. One of the widely accepted possibilities involves the effect of reactive oxygen species. In this review, the mechanism of reactive oxygen species production by sonodynamic therapy (SDT) and ways to enhance the sonodynamic production of reactive oxygen species are reviewed. Then, the clinical application and limitations of SDT are discussed. In conclusion, current research on sonodynamic therapy should focus on the development of sonosensitizers that efficiently produce active oxygen, exhibit biological safety, and promote the clinical transformation of sonodynamic therapy.
Core Tip: This review mainly describes the mechanism of reactive oxygen species generation by sonodynamic therapy and enhances the efficiency of reactive oxygen species generation by improving hypoxia to increase the efficacy of sonodynamic therapy on tumor, and finally summarizes the clinical applications and prospects of sonodynamic therapy.
Citation: Dong HQ, Fu XF, Wang MY, Zhu J. Research progress on reactive oxygen species production mechanisms in tumor sonodynamic therapy. World J Clin Cases 2023; 11(22): 5193-5203
According to the latest statistics from Cancer Statistics, 2023, it is estimated that there will be 1958310 new cancer cases and 609820 cancer deaths in the United States in 2023[1]. Likewise, the cancer situation in China remains critical, with 4.064 million new cases and approximately 2.41 million deaths, according to data released by the National Cancer Centre in 2023[2]. Thus, cancer has become one of the major global threats to human health. Surgery, radiotherapy and chemotherapy are still the main treatment modalities for most malignancies. For example, the standard treatment for ovarian cancer, a common malignancy in women, is extensive tumor reduction surgery in combination with platinum or paclitaxel-based drugs, with or without angiogenesis inhibitors such as bevacizumab[3,4]. Despite the clinical benefits of combining multiple modalities for cancer, the mortality rate of cancer patients unfortunately continues to rise each year: late detection because early symptoms of malignant tumors are atypical, tumor recurrence and metastasis, resistance to therapeutic agents, and the systemic toxicity of treatment are important causes of failure of cancer treatment[5-8]. Therefore, exploring novel cancer therapeutics with higher efficacy, lower toxicity and fewer adverse reactions has become an urgent challenge.
Noninvasive therapies such as high-intensity focused ultrasound (HIFU)[9], photodynamic therapy (PDT)[10], sonodynamic therapy (SDT)[11], and photothermal therapy (PTT)[12] have been widely used in clinical practice and have achieved good therapeutic effects. PDT is a treatment based on reactive oxygen species (ROS) that utilizes a photosensitizer (PS) combined with a specific light source to exert cytotoxic activity on tumor cells[13]. The PS, light and oxygen are the three key factors in PDT, and the combination of the three factors can generate ROS. The antitumor effect of PDT comes from three interrelated mechanisms—the direct cytotoxic effect on tumor cells; the destruction of tumor blood vessels, resulting in the deprivation of nutrients needed for tumors to survive[14]; and the release of cytokines and exosomes by tumor cells, which stimulate the recruitment of immune cells into tumor tissues and promote the antitumor immune response, reducing the mobility and invasion ability of tumor cells[10,15,16]. However, due to adverse factors such as the phototoxicity of PSs, the lack of specific accumulation in malignant tissues, the lack of endogenous oxygen in tumors, and limited light penetration depth (depth < 0.5 cm), PDT has unsatisfactory therapeutic effects on deep tumors, impeding its practical application[17]. Ultrasound has great preclinical and clinical potential due to its noninvasive nature, low energy attenuation and deep tissue penetration[18]. Yumita et al[19] overcame the disadvantages of, such as shallow tissue penetration (depth < 0.5 cm) and phototoxicity, by first proposing SDT to treat solid tumors. SDT is a noninvasive therapeutic modality that synergizes low-intensity and low-frequency ultrasound (0.5-3 W/cm2, 1.0-2.0 MHz) with a sonosensitizer. Its main principle is to irradiate tumor sites with ultrasound under aerobic conditions to achieve the directional activation of sensitizers and a series of sonochemical reactions to kill tumor cells and achieve a therapeutic effect[20]. As an advanced treatment method of low-intensity ultrasound combined with an acoustic sensitizer, SDT has the advantages of high tissue penetration (> 10 cm), high long-range space-time selectivity, and noninvasiveness. It can treat deep lesions that are difficult to access by photodynamic therapy (PDT) and therefore has broad clinical application prospects[18,21].
The therapeutic effect of SDT depends on ROS-mediated oxidative stress. However, the production of ROS is low, and the overexpression of the antioxidant glutathione in tumor tissues leads to high ROS consumption, which significantly reduces the therapeutic effect of SDT[22,23]. Therefore, improving the production capacity of ROS and reducing their consumption are the main strategies to improve the therapeutic effect of SDT[24].
ROS AND THEIR PRODUCTION MECHANISM IN SDT
ROS are a class of oxygen-containing, chemically active substances formed by the incomplete reduction of O2. There are two types of ROS: Free radical ROS and non-free radical ROS. Common ROS include hydrogen peroxide (H2O2), hypochlorous acid, singlet oxygen (1O2), superoxide anion (O2•-), and the hydroxyl group (•OH)[25].
ACOUSTIC CAVITATION
In the 1890s, the British Army found that the propeller of a warship could produce a large number of bubbles during operation, resulting in serious damage to the propeller, which was the first historical description of the cavitation effect[26]. Since then, scientists have performed extensive research on the cavitation effect. It is a special physical phenomenon of ultrasound propagation in liquid[27], referring to a series of dynamic processes including the nucleation, growth and oscillation of microbubbles (cavitation nuclei) in liquid under the action of ultrasound[20]. It can be divided into inertial cavitation and noninertial cavitation. Noninertial cavitation means that under low sound pressure, microbubbles contract under ultrasonic positive pressure and expand under negative pressure, and the bubble diameter remains relatively constant without rupture; inertial cavitation occurs when the sound pressure exceeds the threshold, and microbubbles cannot maintain structural stability in the process of contraction and expansion: therefore, they collapse and implode in the compression stage and produce local high temperature (4000-25000 K) and high pressure (81 MPa) instantaneously, accompanied by high-speed shockwaves, microjets and sonochemical effects[20]. SDT produces ROS through sonoluminescence and pyrolysis[28]. The mechanism of ROS production by sonoluminescence is similar to that of PTD, which stimulates the production of active oxygen by sonosensitizers through type I and type II reactions (Figure 1A)[29]. In the type I reaction, under the action of ultrasound, the sonosensitizer is excited from the ground state S0 to the excited state S1 and then changes to the excited triplet state (T1) through internal conversion. The T1 sonosensitizer reacts with the intracellular matrix to produce ROS (H2O2, 1O2,•OH)[30]. The energy generated by the cavitation effect in the type II reaction is directly transferred to excited 3O2 to produce 1O2[30,31]. The mechanism by which pyrolysis produces ROS includes the implosion of transient cavitation microbubbles to generate high temperature instantaneously: this high temperature directly decomposes H2O to produce •H and •OH, which can react with the sonosensitizer to produce ROS with a longer half-life[32]. In addition, the sonosensitizer can directly decompose at high temperature to generate free radicals, which further react with endogenous substances to generate other active forms of oxygen (Figure 1B)[32].
Piezoelectric catalysis is an emerging active ROS generation method, especially in SDT, that can directionally trigger the generation of in situ ROS in particular[33]. When not mechanically stimulated, piezoelectric materials are in electrostatic equilibrium[34]. When ultrasound acts on piezoelectric materials, they are subjected to rapid periodic mechanical stimulation[33], and the polarization amplitude oscillates rapidly with the piezoelectric force field, resulting in the continuous separation of electrons and holes in piezoelectric materials and establishing a built-in electric field in piezocatalysts. This in turn catalyzes the generation of toxic •OH and •O2− (Figure 1B)[34-36].
METHODS TO IMPROVE THE GENERATION OF ROS
Improving the hypoxic tumor microenvironment
The tumor microenvironment (TME) refers to the cellular environment in which tumors or tumor stem cells exist[37], including cancer-associated fibroblasts, vascular endothelial cells, and extracellular matrix[38], characterized by low pH, low oxygen (PO2 ≤ 2.5 mmHg), high H2O2 (50-100 × 10-6 mmol/L), glucose deprivation, and so on[39-41]. Hypoxia is one of the common and important characteristics of malignant tumors and is mainly caused by the imbalance between oxygen supply and consumption in tumor tissues[38]. The relevant mechanisms include oxygen perfusion limitation, oxygen diffusion limitation and anemic hypoxia[42]. Based on the dynamic changes in the TME, hypoxia is divided into acute hypoxia and chronic hypoxia. Acute hypoxia is related to perfusion and is caused by the instability of red blood cell flux in the tumor microvascular network, while chronic hypoxia is long-term or irreversible and is related to oxygen diffusion limitation[38].
Hypoxia inducible factor is activated by hypoxia and plays an important role in tumor progression, metastasis and immune escape, thus making tumors more resistant to many current treatments[43]. An increasing volume of data indicates that tumor hypoxia is the main reason for the failure of many current therapies. As the substrate for SDT to produce ROS, tumor hypoxia will inevitably affect the production efficiency of ROS and reduce the efficacy of SDT. Therefore, adding in situ oxygen-generating materials or oxygen carriers to sonosensitizers to increase the oxygen content in the TME and increase the efficacy of SDT has become a new tumor treatment approach[44-46].
IN SITU O2 GENERATION
Catalase (CAT) can catalyze endogenous H2O2 in tumors to generate O2, which is an effective method to overcome tumor hypoxia. One researcher designed a thermotriggered in situ hydrogel system (TCCP-CAT CS/GP) based on the catalytic properties of CAT, which couples meso-tetra (4-carboxyphenyl) porphine (TCCP) with CAT and then mixes it with chitosan (CS) and disodium β-glycerophosphate (GP) to form a solution. At mouse body temperature (37 °C), this acoustic sensitizer was injected into the tumor site and was able to undergo sol-gel conversion, leaving the acoustic sensitizer at the tumor site. CAT catalyzed the original hydrogen peroxide to produce O2, continuously relieving tumor hypoxia, promoting TCCP to produce large amounts of ROS, and exerting a tumor suppression effect[47]. Since the first report of Fe3O4 magnetic nanoparticles with intrinsic peroxidase-like activity in 2007[48], several O2-releasing nanosystems (e.g., manganese dioxide nanoparticles[49,50], gold nanoclusters, and Fe3+-doped structural units) have been shown to be transported to tumor sites to catalyze the conversion of endogenous H2O2 to O2 and alleviate tumor hypoxia. For instance, manganese dioxide (MnO2) nanoparticles have been reported to possess catalase properties, high reactivity with H2O2, and the ability to continuously produce O2 and were shown to effectively alleviate tumor hypoxia. Piao Zhu et al. introduced MnOx into hollow mesoporous organosilica nanoparticles (HMONs) in situ through a simple redox reaction, anchored PpIX with HMONs, MnOx, and cyclic arginine-glycine-aspartic pentapeptide (RGD, as a targeting peptide) to modify the surface of nanoparticles, and finally constructed a multifunctional nanosonosensitizer (PpIX@HMON-MnOx-RGD) (Figure 2A). Both in vivo and in vitro experiments showed that MnOx can act as a nanoenzyme, catalyze the decomposition of excessive H2O2 in tumors, produce oxygen (Figure 2B), alleviate tumor hypoxia, provide a sufficient oxygen source for SDT, promote the production of reactive oxygen species (Figure 2C), and improve the efficacy of SDT (Figure 2D and E)[51]. In addition, platinum (Pt) nanocrystals can be used as nanoenzymes to decompose H2O2 and produce a large amount of O2. Based on the characteristics of Pt nanocrystals, Tian Zhang et al. constructed a Pt nanocrystal-encapsulated sonosensitizer (α-Fe2O3@Pt), and the pairing of α-Fe2O3 and Pt formed an effective electron capture trap to prevent the recombination of electrons and holes and promote the generation of 1O2 (Figure 3). At the same time, Pt, as a nanoenzyme, can decompose H2O2 to generate a large amount of O2, which is a more effective means of O2 generation for SDT and the effective inhibition of tumor growth[52]. Nevertheless, the methods mentioned above inevitably consume H2O2, resulting in an insufficient supply of H2O2 in the SDT process. Based on this shortcoming, Jiang et al[53] developed an H2O2 economizer, namely, membrane-coated Fe-PDAP/Ce6 (MFC) coated with cancer cell membrane. Prior to ultrasound irradiation, the cancer cell membrane coated with the acoustic sensitizer could prevent the early release of catalase-like nanoenzyme Fe-PDAP and reduce the unnecessary consumption of H2O2 in the TME. After ultrasonic irradiation, MFC could be selectively dismantled to release Fe-PDAP, which could catalyze H2O2 to generate O2 and more effectively produce ROS.
Due to the limited H2O2 available in the TME and the inability to continuously provide O2[54], oxygen carriers (hemoglobin[55], microbubbles[56], fluorocarbon[57]) and sonosensitizers can better alleviate tumor hypoxia.
Hemoglobin (Hb), as a natural oxygen carrier, can bind four oxygen atoms per Hb unit. At the same time, the generation of ultrasonic-induced active ROS provides a rich source of oxygen. In one study, a pH-sensitive zeolitic imidazolate framework (ZIF-8) was used as the carrier to encapsulate Hb and synthesize Hb@ZIF-8 (HZ) to achieve the release of pH-responsive Hb/O2 at the tumor site[58]. In vitro experiments showed that adjusting the pH 5.5 could release a large amount of O2, alleviate tumor hypoxia, generate a large amount of ROS under ultrasonic response, activate the mitochondrial apoptosis pathway, and effectively inhibit the growth of tumor cells. In vivo experiments revealed that nanoparticles irradiated by ultrasound can not only inhibit the growth of subcutaneous tumors but also control the growth of deep tumors, revealing that SDT can be applied at different depths.
Furthermore, perfluorocarbons (perfluorobutane, perfluoropentane and the like) are widely used for the delivery of chemotherapeutic drugs, genes, oxygen, or contrast agents due to their high oxygen solubility and biocompatibility[59,60]. Studies have shown that perfluorocarbon carries oxygen more efficiently than Hb, with 100 mL of perfluorocarbon carrying approximately 40 to 50 mL of O2 at 25℃, whereas the same volume of Hb carries only 20 mL of O2[61,62]. Chen et al[57] successfully developed the fluorocarbon-chain-media oxygen-self-produced nanoplatform (IR780@O2-FHMON). Both cellular and in vivo experiments have shown that the nanoplatform can better accumulate in tumors, accelerate the release of O2, permanently reverse hypoxia, and generate more ROS to achieve the high-efficiency treatment of PANC-1 pancreatic cancer by SDT. Yang et al[63] also reported a hierarchical nanoformulation (PFCE@THPPpf-COPs) that can effectively alleviate hypoxia ub prostate cancer, generate a large amount of ROS, improve the curative effect of SDT, and achieve tumor eradication through the high-loading oxygen carrier perfluoropolyether.
REDUCING THE ROS SCAVENGING CAPACITY
Glutathione (GSH), an important nonprotein mercaptan that contains thiols and amide linkages, is a major intracellular antioxidant that plays a key role in many physiological and pathological processes[64,65]. In addition to hypoxia, the overexpression of glutathione (1-10 × 10-3 mmol/L) is also an important feature of the TME[66]. High levels of glutathione can protect cancer cells from ROS-induced oxidative damage. Therefore, as SDT is an active oxygen-based therapy, excessive glutathione in the TME can negatively affect the efficacy[64]. At present, the intracellular glutathione level is mainly reduced through two pathways, namely, the upstream and downstream pathways of glutathione[67]. The glutathione upstream pathway refers to the inhibition of glutathione synthesis by cancer cells through the use of glutathione biosynthesis inhibitors, such as L-butynyl sulfoxide amine (BSO) and γ-glutamyl cysteine synthetase[68]. For example, a study successfully synthesized BSO-TCPP-Fe@CaCO3-PEG nanoparticles, which amplified the oxidative stress of tumors through Ca2+ overload-induced ROS generation, BSO-mediated GSH synthesis inhibition and meso-tetra-(4-carboxyphenyl) porphine (TCPP)-mediated sonodynamic effects, leading to significant cancer cell death and overall effective inhibition of tumor growth to enhance the therapeutic effect of SDT[68]. The downstream pathway refers to the conversion of GSH to glutathione disulfide through a redox reaction between glutathione and some reducing agents. For example, Huang et al[64] designed GSH-depleting nanoplatelets consisting of cinnamic aldehyde (CA) and IR780-supported mesoporous silica nanoparticles (MSNs) coated with a platelet membrane called PV-coated MSN-CA/IR780 (PSCI). CA, serving as an oxidative stress amplification agent, consumes excessive glutathione in the TME, weakens the ability of tumor cells to produce active oxygen by eliminating SDT through glutathione, increases the content of active oxygen, and further enhances the therapeutic effect of SDT to effectively inhibit tumor growth.
CLINICAL APPLICATION AND LIMITATIONS OF SDT
Although good progress has been made in preclinical studies on SDT (Table 1), no large-scale clinical studies have been executed, and only a few cases have been reported. All the existing studies have combined SDT with other treatments (chemotherapy, hormone therapy, and immunotherapy)[69,70]. For example, Wang et al[71] reported the clinical results of SDT combined with photodynamic therapy (SPDT) after treating 3 patients with advanced refractory breast cancer. After sublingual absorption of the acoustic sensitizer SF1 for 2 to 3 d, the tumor area or the whole body was irradiated with a red LED lamp (wavelength: 630 nm, power: 20 Mw/cm2) for 30 min, and then the tumor area was irradiated with a portable ultrasound device (frequency: 1 MHz, power: 2.0 W/cm2) for 20 min for a continuous period of 3 d. After treatment, the tumors in all three patients were significantly reduced, and there was no significant effect of SPDT on vital organs throughout the body. Subsequently, Inui et al[72] used SDT in combination with immunotherapy to treat a patient with advanced breast cancer (invasive ductal carcinoma, grade 3, ER+, PR+, HER2+, right axillary, spinal, and pleural metastases). After 19 sessions of sonodynamic therapy with SDT (5-ALA (10 mg/kg)-modified Ce 6 (25 mg) in combination with exemestane (25 mg/d), the tumor in the right axilla and pleura completely disappeared, and tumor markers rapidly declined without serious side effects.
Table 1 Application of sonodynamic therapy in different tumors.
Cancer type
Sonosensitizer
Therapeutic parameters
Result
Ref.
Glioma
Ce6
0.6 W/cm2, 60 s
SDT inhibits xenograft tumor growth by inducing apoptosis and inhibiting mitochondrial autophagy
Mn-MOF catalyzes the in situ production of O2 to alleviate tumor hypoxia and reduce GSH and GPX4, which contributes to ROS formation and iron death, thereby killing cancer cells
The combination of SDT and aPD-L1 immunotherapy effectively inhibits tumor infiltration and promotes activation of cytotoxic T cells, resulting in strong anticancer immunity and long-term immune memory, effectively inhibiting melanoma growth
IR780 selectively positions the nanoparticles into the mitochondria of cancer cells, and generates the acoustic droplet vaporization effect after perfluorohexane phase transition to achieve the synergistic treatment of tumors
pH- and histone B-responsive nanoparticles combined with SDT have a significant induced cytotoxic effect on prostate cancer cells and can effectively treat cancer
Construction of an ultrasound microbubble using pyrophosphorylated lipids in combination with trastuzumab for the synergistic treatment of HER2-positive gastric cancer with sonodynamic therapy and antibody therapy
In the abovementioned examples, SDT combined with other treatments showed good therapeutic effects, but it is difficult to quantify the role of SDT in treatment success[70]. Most acoustic sensitizers have low biosafety and ROS-producing ability, resulting in insufficient efficacy to replace traditional antitumor therapy. Therefore, SDT has not become widespread in clinical practice. The following problems exist regarding SDT: (1) The therapeutic mechanism of SDT has not been fully elucidated[73]; (2) there are relatively few ultrasonic treatment devices suitable for clinical application[74]; (3) for different types of tumors, more detailed studies are needed on the key parameters of ultrasonic frequency, intensity and irradiation time[11,75]; (4) further research is needed on sound-sensitive agents with good photoacoustic dynamic effects and biocompatibility[76]; and (5) the biosafety of various kinds of sonosensitizers needs to be systematically studied in vivo and in vitro. In particular, inorganic sonosensitizers have poor biodegradability and are not easily metabolized[77]. Currently, the sonosensitizers approved by the Food and Drug Administration of the United States are mainly organic acoustic sonosensitizers[11], such as indocyanine green[44], sodium warfarin (DVDMS)[78], chlorin e6[60] and 5- aminolevulinic acid[79].
CONCLUSION
SDT, which relies on the strong penetration of ultrasound and the tumor-specific accumulation of sonosensitizers, has been proven to be an effective, low-cost and safe antitumor treatment technique with good clinical application prospects[80]. SDT mainly relies on the research and development of sonosensitizers and the alleviation of the tumor hypoxic microenvironment to promote the efficient production of reactive oxygen species by sonosensitizers. Therefore, the development of sonosensitizers with strong ROS generation ability and good biodegradability will help SDT to obtain better clinical application prospects. In short, SDT has been proven to have good therapeutic effects on tumors, but most of these effects are based on preclinical research. In the future, more research efforts are needed to promote the clinical transformation of SDT[21,32].
ACKNOWLEDGEMENTS
Many thanks to Professor Jiang Zhu for her careful guidance and many valuable comments on the thesis, and to Minyan Wang and Xiaofeng Fu for his contribution in collecting the relevant materials.
Footnotes
Provenance and peer review: Unsolicited article; Externally peer reviewed.
Peer-review model: Single blind
Specialty type: Radiology, nuclear medicine and medical imaging
Sato H, Yoshida R, Yasui K, Umeda Y, Yoshida K, Fuji T, Kumano K, Takagi K, Yagi T, Fujiwara T. Feasibility of local therapy for recurrent pancreatic cancer.Pancreatology. 2022;22:774-781.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 4][Reference Citation Analysis (0)]
Wang P, Tang Q, Zhang L, Xu M, Sun L, Sun S, Zhang J, Wang S, Liang X. Ultrasmall Barium Titanate Nanoparticles for Highly Efficient Hypoxic Tumor Therapy via Ultrasound Triggered Piezocatalysis and Water Splitting.ACS Nano. 2021;15:11326-11340.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 49][Cited by in F6Publishing: 66][Article Influence: 22.0][Reference Citation Analysis (0)]
Jiang Q, Qiao B, Lin X, Cao J, Zhang N, Guo H, Liu W, Zhu L, Xie X, Wan L, Tang R, Liang B, Wang D, Wang Z, Zhou Y, Ran H, Li P. A hydrogen peroxide economizer for on-demand oxygen production-assisted robust sonodynamic immunotherapy.Theranostics. 2022;12:59-75.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 9][Cited by in F6Publishing: 41][Article Influence: 20.5][Reference Citation Analysis (0)]
McEwan C, Kamila S, Owen J, Nesbitt H, Callan B, Borden M, Nomikou N, Hamoudi RA, Taylor MA, Stride E, McHale AP, Callan JF. Combined sonodynamic and antimetabolite therapy for the improved treatment of pancreatic cancer using oxygen loaded microbubbles as a delivery vehicle.Biomaterials. 2016;80:20-32.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 88][Cited by in F6Publishing: 103][Article Influence: 11.4][Reference Citation Analysis (0)]
van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, van der Velden J, Arts HJ, Massuger LFAG, Aalbers AGJ, Verwaal VJ, Kieffer JM, Van de Vijver KK, van Tinteren H, Aaronson NK, Sonke GS. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.N Engl J Med. 2018;378:230-240.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 844][Cited by in F6Publishing: 912][Article Influence: 152.0][Reference Citation Analysis (0)]
Inui T, Makita K, Miura H, Matsuda A, Kuchiike D, Kubo K, Mette M, Uto Y, Nishikata T, Hori H, Sakamoto N. Case report: A breast cancer patient treated with GcMAF, sonodynamic therapy and hormone therapy.Anticancer Res. 2014;34:4589-4593.
[PubMed] [DOI][Cited in This Article: ]
Raspagliesi L, D'Ammando A, Gionso M, Sheybani ND, Lopes MB, Moore D, Allen S, Gatesman J, Porto E, Timbie K, Franzini A, Di Meco F, Sheehan J, Xu Z, Prada F. Intracranial Sonodynamic Therapy With 5-Aminolevulinic Acid and Sodium Fluorescein: Safety Study in a Porcine Model.Front Oncol. 2021;11:679989.
[PubMed] [DOI][Cited in This Article: ][Cited by in F6Publishing: 14][Reference Citation Analysis (0)]
Hadi MM, Farrell S, Nesbitt H, Thomas K, Kubajewska I, Ng A, Masood H, Patel S, Sciscione F, Davidson B, Callan JF, MacRobert AJ, McHale AP, Nomikou N. Nanotechnology-augmented sonodynamic therapy and associated immune-mediated effects for the treatment of pancreatic ductal adenocarcinoma.J Cancer Res Clin Oncol. 2022;.
[PubMed] [DOI][Cited in This Article: ][Cited by in F6Publishing: 4][Reference Citation Analysis (0)]
Zhou J, Hou J, Liu S, Xu J, Luo Y, Zheng J, Li X, Wang Z, Ran H, Guo D. Theranostic Nanoplatform with Sequential SDT and ADV Effects in Response to Well-Programmed LIFU Irradiation for Cervical Cancer.Int J Nanomedicine. 2021;16:7995-8012.
[PubMed] [DOI][Cited in This Article: ][Reference Citation Analysis (0)]
Xie W, Zhu S, Yang B, Chen C, Chen S, Liu Y, Nie X, Hao L, Wang Z, Sun J, Chang S. The Destruction Of Laser-Induced Phase-Transition Nanoparticles Triggered By Low-Intensity Ultrasound: An Innovative Modality To Enhance The Immunological Treatment Of Ovarian Cancer Cells.Int J Nanomedicine. 2019;14:9377-9393.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 25][Cited by in F6Publishing: 39][Article Influence: 7.8][Reference Citation Analysis (0)]
Hadi MM, Nesbitt H, Masood H, Sciscione F, Patel S, Ramesh BS, Emberton M, Callan JF, MacRobert A, McHale AP, Nomikou N. Investigating the performance of a novel pH and cathepsin B sensitive, stimulus-responsive nanoparticle for optimised sonodynamic therapy in prostate cancer.J Control Release. 2021;329:76-86.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 17][Cited by in F6Publishing: 30][Article Influence: 10.0][Reference Citation Analysis (0)]
